北京若生智能科技有限公司
Drug Database
SC

Scherersol delivery systems (Polysol / Quadrisol / Cosol)

✓ Approved

Cardinal Health, Inc. · 小分子 · 小分子

什么是 Scherersol delivery systems？

Scherersol delivery systems 是一种小分子，由Cardinal Health, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Polysol, Quadrisol, Cosol
公司Cardinal Health, Inc.
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Cardinal Health, Inc.

治疗适应症

Scherersol delivery systems 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedAAPS PharmSciTech2026-09-10

From Liquid to Gel: Multifunctional Stimuli-responsive Polymers for Targeted Oral Drug Delivery.

Mishra Manoj Kumar MK, Shukla Divaker D, Sharma Shalini S, Sharma Jyoti Nanda JN et al.

Oral drug delivery is the delivery method of choice, as it is non-invasive and patients will comply with the delivery method, but many contemporary therapeutics, such as poorly soluble, permeable, and unstable drugs, fail because of rapid gastrointestinal absorption, enzyme degradation, and non-targetability. The in-situ gelling systems are now considered paradigms that no longer exist as liquids; instead, they form a depot in the gastrointestinal tract and transform into a gel in response to physiological signals such as pH, ions, or enzymes. This review will discuss how these so-called smart polymers have developed over the years, starting as simple gel-forming systems and evolving into the multifunctional platforms that are also designed to have a pointed and sustained action. Next generation in situ gels combine bioadhesion, permeation enhancement, and active targeting ligands to overcome sequential barriers to delivery transit, permeability, stability, and cellular uptake. We critically assess the chemistry, mechanisms, formulation strategies, and therapeutic use of these systems, including gastro-retention and localized therapy, as well as oral delivery of biologics. Despite encouraging preclinical results, we touch on translational issues of scalability, manufacturing, and regulatory pathways. Multifunctional stimuli-responsive polymers, which actively traverse the gastrointestinal environment, are the future of oral drug delivery because they provide precision, bioavailability, and improved patient outcomes.

PMID 42717126
阅读全文 →
PubMedAAPS PharmSciTech2026-09-10

Solid Lipid Nanoparticles Based Dry Powder Inhalers for Enhanced Drug Delivery Against Lung Diseases.

Onel Cagla C, Pirincci Tok Yagmur Y, Ozsoy Yildiz Y

The global incidence of lung diseases associated with high mortality and morbidity rates is projected to rise in the coming years. Conventional therapies face limitations such as low bioavailability and systemic side effects with oral administration, as well as poor patient compliance and frequent dosing with traditional inhalers. These shortcomings have created an urgent need for novel pulmonary drug delivery systems. In recent years, nanoparticulate drug carriers have gained significance for their potential to enable targeted lung delivery and reduced dosing frequency. Among them, solid lipid nanoparticles (SLNs) have attracted considerable attention due to their biocompatible and biodegradable structures, controlled release capabilities, organic solvent-free production processes and favorable aerodynamic behavior. This review provides a comprehensive perspective to guide the rational design of SLN-based dry powder inhaler (DPI) systems by integrating formulation strategies, production techniques, surface functionalization, and DPI development, with the goal of enhancing therapeutic outcomes in respiratory diseases such as cancer, infections, chronic obstructive pulmonary disease, and cystic fibrosis.

PMID 42717150
阅读全文 →
PubMedFrontiers in immunology2026-09-10

Advances in nanomaterial-based delivery systems for inducing transplantation tolerance.

Li Qingqing Q, Zhang Yun Y, Wu Jinwei J, Huang Dongxing D et al.

Organ transplantation is the primary therapeutic approach for patients with end-stage organ failure. However, challenges such as transplant rejection, the toxic side effects of long-term systemic immunosuppression, and substantial economic burdens remain pressing issues in clinical practice. The goal of inducing donor-specific transplantation tolerance is considered the most effective strategy to address these problems. Conventional tolerance-inducing strategies, including hematopoietic chimerism establishment, costimulatory signal blockade, and regulatory cell therapy, are often hampered by key limitations such as myeloablative toxicity, resistance from memory T cells, high costs associated with ex vivo cell expansion, and poor in vivo stability. This review summarizes the types and properties of nanomaterials used to induce transplantation tolerance, systematically discusses their payload categories and immunoregulatory mechanisms, and delineates key delivery strategies and in vivo mechanisms. Furthermore, it analyzes current challenges and bottlenecks faced by nanodelivery systems. Finally, future perspectives on optimizing and translating these systems into clinical applications are proposed, providing valuable insights for developing safe, precise, and efficient strategies for transplantation tolerance induction.

PMID 42719113
阅读全文 →
PubMedBioengineering & translational medicine2026-09-10

From bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling.

Parrot Madison M, Xu Nuo N, Adnan Md M, Cave Joseph J et al.

Nanoparticles represent a major advancement in drug delivery, enhancing stability, solubility, and targeted delivery while reducing non-specific toxicity. Despite promising preclinical results, few nanoparticle platforms have successfully translated to clinical use due to limited pharmacokinetic (PK) data, off-target effects, manufacturing complexity, and a lack of long-term studies. Emphasizing the pivotal role of PK in this development process is essential for harnessing the full therapeutic potential of nanoparticle applications in clinical practice. In this review, we introduce the concept of model-informed nanoparticle development (MIND), an extension of model-informed drug development (MIDD) principles to nanomedicine that integrates knowledge of nanoparticle interactions with biological systems and state-of-the-art pharmacokinetic modeling to support evidence-based decision-making. Physiologically-based PK (PBPK) models simulate the absorption, distribution, metabolism, and elimination (ADME) of nanoparticles within the body, incorporating physiological parameters to predict their PK behavior. Population-based PK (PopPK) models utilize population variability to characterize nanoparticle PK across diverse patient groups, optimizing dosing strategies and personalized medicine approaches. Mechanistic models elucidate the intricate interactions between nanoparticles and biological systems, integrating cellular pathways and disease mechanisms to predict therapeutic outcomes and guide nanoparticle design. Through the MIND framework, these modeling approaches can enhance our understanding of nanoparticle PK, foster innovation in active agent delivery systems, and accelerate nanoparticle translation from research to clinical applications.

PMID 42718899
阅读全文 →
PubMedDiabetes technology & therapeutics2026-09-10

Long-Term Clinical and Economic Impact of Automated Insulin Delivery Systems Use in Pediatric and Adolescents Type 1 Diabetes: Results Across Australia, Canada, the UK, and the USA.

Legault Laurent L, Sherr Jennifer L JL, Davis Elizabeth A EA, Cerezales Mónica M et al.

Automated Insulin Delivery (AID) systems are the recommended standard of care for Type 1 Diabetes (T1D) management in children and adolescents, according to latest international guidelines. This study aims to assess the cost-effectiveness of AID systems for pediatric T1D care in Australia, Canada, the United Kingdom (UK), and the United States (USA). The IQVIA Core Diabetes Model was used to compare AID systems with Multiple Daily Injections and Continuous Glucose Monitoring (MDI+CGM). Data were sourced from the National Health System (NHS) England real-world AID pilot initiative, a prospective follow-up study of 251 children and adolescents with T1D that showed a 0.63% reduction in HbA1c following the first year of system use. Clinical and economic outcomes were analyzed over a 55-year time horizon from a health care system perspective, applying country-specific discount rates and direct costs to estimate cost-effectiveness ratios (ICERs). AID systems were associated with Quality-Adjusted Life Years (QALYs) gains ranging from 1.35 to 2.72 across all countries. AID use resulted in significant relative risk reduction for long-term complications, such as proliferative diabetic retinopathy (51.3%), end-stage renal disease (39.5%), and severe vision loss (38.8%). Total cost savings ranged from USD-9340 in Australia to USD-28,798 in Canada. AID use was associated with an ICER of 14,590 in Australia, 25,798 in Canada, 32,459 in the UK, and 35,648 in USA per QALY gained (all values in USD). AID therapy was predicted to reduce mid- and long-term diabetes-related complications and improve quality of life while concomitantly reducing the economic burden on health care systems. AID was projected to be cost-effective versus MDI+CGM for pediatrics and adolescents with T1D in all analyzed countries. These findings highlight the need to accelerate the adoption of AID systems and to secure universal access and funding during this vulnerable period of life.

PMID 42719944
阅读全文 →
PubMedChemical record (New York, N.Y.)2026-09-10

From Barrier Disruption to Precision Skin Interface Engineering: Next-Generation Transdermal Drug Delivery.

Zhou Cong-Zheng CZ, Lin Xin-Yu XY, Yu Shou-Shan SS, Qiao Sheng-Lin SL

Transdermal drug delivery (TDD) is reemerging as a clinically attractive route for noninvasive therapy, driven by the growing demand for alternatives to repeated injection and by the rapid development of materials capable of regulating transport across the skin. By avoiding gastrointestinal degradation and hepatic first-pass metabolism, TDD can provide prolonged drug exposure, reduce peak-to-trough fluctuations in plasma concentration, and improve adherence in long-term treatment. Its broader implementation, however, is still constrained by the exceptional barrier function of the stratum corneum, which severely limits the passive transport of hydrophilic molecules, charged species, and macromolecular therapeutics. In this review, we critically discuss the structural basis of the skin barrier and summarize the evolution of TDD strategies from conventional chemical permeation enhancement and device-assisted physical disruption to nanocarrier-mediated, biomimetic, and intelligent bio-delivery systems. Particular emphasis is placed on the mechanistic logic that connects carrier composition, interfacial interactions, skin microenvironment remodeling, and therapeutic performance. Representative examples are analyzed to highlight both opportunities and translational bottlenecks. Finally, we outline future directions in multimodal delivery, pathology-adapted design, standardized evaluation, and scalable manufacturing, which will be essential for transforming TDD from a permeability enhancement technology into a precision-regulated therapeutic platform.

PMID 42717625
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Scherersol delivery systems